机读格式显示(MARC)

• 000 03607cam a2200409 i 4500

• 001 0001420628

• 003 CAL

• 005 20240626144000.0

• 008 211228s2022 flua b 001 0 eng

• 020 __ |a 9781138594227 |q (hardback)

• 020 __ |a 1138594229 |q (hardback)

• 020 __ |a 9781032262024 |q (paperback)

• 020 __ |a 1032262028 |q (paperback)

• 020 __ |z 9780429485626 |q (ebook)

• 040 __ |a DLC |b eng |e rda |c DLC |d OCLCO |d OCLCF |d OCLCO |d Y@Y

• 042 __ |a pcc

• 050 00 |a RS380 |b .B536 2022

• 082 00 |a 615.1/9 |2 23/eng/20211228

• 090 __ |a R945/M1

• 093 __ |a R918 |2 5

• 099 __ |a CAL 022022079052

• 245 00 |a Biologics and biosimilars : |b drug development and clinical affairs / |c edited by Xiaodong Feng, Hong-Guang Xie, Ashim Malhotra, Catherine F. Yang.

• 250 __ |a First edition.

• 264 _1 |a Boca Raton, FL : |b Taylor and Francis, |c 2022.

• 300 __ |a xviii, 510 pages : |b illustrations ; |c 26 cm

• 336 __ |a text |b txt |2 rdacontent

• 337 __ |a unmediated |b n |2 rdamedia

• 338 __ |a volume |b nc |2 rdacarrier

• 504 __ |a Includes bibliographical references and index.

• 505 0_ |a Biologics and Biosimilars 101: Principles and Practice -- Frontiers in Biopharmaceutical Development of Biologics and Biosimilars: Opportunities and Challenges -- Biologics and Biosimilars: Research and Development -- Vaccines as Biologics in the Era of Pandemic -- Therapeutic Delivery Systems for Biologics and Biosimilars -- Legislative and Regulatory Pathways for Biosimilars -- The Development of Biologics from the Perspective of the Pharmaceutical Industry -- The Manufacturing and Quality Assurance Process for Biologics and Biosimilars -- Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics of Biological Products -- Understanding Variability, Stability, and Immunogenicity of Biosimilars -- Expanding the Product Shelf: Taking Biologics and Biosimilars from the Bench to the Bedside -- Hydrogel-Based Delivery of Biologics in Cancer and Cardiovascular Diseases: Proof-of-Concept -- Clinical Use of Biologics and Biosimilars in Oncology Settings -- Monoclonal Antibodies in Cancer Therapeutics -- Molecule-Targeted Drugs That Treat Colorectal Cancer -- Rising from the Ashes: The Curious Case of the Development of Biologics for the Treatment of Neuroblastoma -- Paradigm Shift in Cancer Therapy: Chimeric Antigen Receptor T Cell Therapy -- Biologics and Biosimilars Used for Diabetes -- Clinical Use of Biologics and Biosimilars in Asthma -- Biologics and Biosimilars: Potential Therapeutics for Autoimmune Renal Diseases -- Therapeutics of Recombinant Human Clotting Factor VIII (rhFVIII) for Hemophilia A -- Complement as New Immunotherapy Target: Past, Present, and Future -- Drug Discovery Approaches for Inflammatory Bowel Disease: Antibodies and Biosimilars -- Transformative Stem Cell-Based Therapy in Neurological Diseases and Beyond -- Biologics and Biosimilars: Clinical Applications and Biomarker Testing -- Application of Modeling and Simulation in the Development of Biologics and Biosimilars -- Machine Learning Applications in Biologics and Biosimilars: Disruptive Innovation.

• 520 __ |a "Biologics and Biosimilars: Drug Development and Clinical Affairs is a systematic integration and evaluation of all aspects of biologics and biosimilars, R&D and clinical use, global regulation, and more"-- |c Provided by publisher.

• 650 _0 |a Pharmaceutical biotechnology.

• 650 _0 |a Drug development.

• 700 1_ |a Feng, Xiaodong, |e editor.

• 700 1_ |a Xie, Hong-Guang, |e editor.

• 700 1_ |a Malhotra, Ashim, |d 1977- |e editor.

• 700 1_ |a Yang, Catherine F., |e editor.